Effect of Standard vs Intensive Blood Pressure Control on Cerebral Blood Flow in Small Vessel Disease: The PRESERVE Randomized Clinical Trial

Abstract

Importance: Blood pressure (BP) lowering is considered neuroprotective in patients with cerebral small vessel disease; however, more intensive regimens may increase cerebral hypoperfusion. This study examined the effect of standard vs intensive BP treatment on cerebral perfusion in patients with severe small vessel disease.

Objective: To investigate whether standard vs intensive BP lowering over 3 months causes decreased cerebral perfusion in small vessel disease.

Design, setting, and participants: This randomized clinical trial took place at 2 English university medical centers. Patients were randomized via a central online system (in a 1:1 ratio). Seventy patients with hypertension and with magnetic resonance imaging-confirmed symptomatic lacunar infarct and confluent white matter hyperintensities were recruited between February 29, 2012, and October 21, 2015, and randomized (36 in the standard group and 34 in the intensive group). Analyzable data were available in 62 patients, 33 in the standard group and 29 in the intensive group, for intent-to-treat analysis. This experiment examines the 3-month follow-up period.

Interventions: Patients were randomized to standard (systolic, 130-140 mm Hg) or intensive (systolic, <125 mm Hg) BP targets, to be achieved through medication changes.

Main outcomes and measures: Cerebral perfusion was measured using arterial spin labeling; the primary end point was change in global perfusion between baseline and 3 months, compared between treatment groups by analysis of variance. Linear regression compared change in perfusion against change in BP. Magnetic resonance imaging scan analysis was masked to treatment group.

Results: Among 62 analyzable patients, the mean age was 69.3 years, and 60% (n = 37) were male. The mean (SD) systolic BP decreased by 8 (12) mm Hg in the standard group and by 27 (17) mm Hg in the intensive group (P < .001), with mean (SD) achieved pressures of 141 (13) and 126 (10) mm Hg, respectively. Change in global perfusion did not differ between treatment groups: the mean (SD) change was -0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η2, 0.004; 95% CI, -3.551 to 5.818; P = .63). No differences were observed when the analysis examined gray or white matter only or was confined to those achieving target BP. The number of adverse events did not differ between treatment groups, with a mean (SD) of 0.21 (0.65) for the standard group and 0.32 (0.75) for the intensive group (P = .44).

Conclusions and relevance: Intensive BP lowering did not reduce cerebral perfusion in severe small vessel disease.

Trial registration: isrctn.org Identifier: ISRCTN37694103.

Conflict of interest statement

Conflict of Interest Disclosures: Dr O’Brien reported having financial affiliations with GE Healthcare, TauRx, Avid/Lilly, and Axon. Dr Ford reported having financial affiliations with Pfizer, Medtronic, AstraZeneca, Boehringer Ingelheim, Athersys, Cerevast, Daiichi Sankyo, and Pulse Therapeutics. No other disclosures were reported.

Figures

Figure 1.. CONSORT Diagram

Shown is an overview of the participant flow, sample sizes, and dropout characterization for this analysis. ASL indicates arterial spin labeling; CONSORT, Consolidated Standards of Reporting Trials; FLAIR, fluid-attenuated inversion recovery; and MRI, magnetic resonance imaging.

Figure 2.. Change in Whole-Brain Cerebral Blood Flow (CBF)

The spaghetti plot shows the change for each participant by treatment group.